Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547667 | 0.69 | HDAC1 (0.40) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL28403663 | 0.68 | CYP2A6 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3853216 | 0.68 | SIRT1 (0.31) | — | |
| SCHEMBL14724654 | 0.68 | ERN1 (0.33) | — | |
| SCHEMBL12077653 | 0.68 | LPL (0.36) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL26817468 | 0.67 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16018872 | 0.66 | — | — | |
| SCHEMBL12594000 | 0.65 | TUBB1 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL48658 | 0.64 | CES2 (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL31085187 | 0.63 | TSHR (0.39) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | ALDH1A1 4010/4885SMN1; SMN2 3273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.